Clinical Trial Update: Pasireotide LAR in Severe Polycystic Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of pasireotide LAR in severe polycystic liver disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease
• Autosomal Dominant Polycystic Liver Disease
• Polycystic Liver Disease

Drugs mentioned

• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Mayo Clinic | Conditions: Somatostatin Analogs, Polycystic Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-03-02